TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32066497
Drug: 2 g/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/8 h by continuous infusion (CI)
Study: 32066497
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day (theoretical highest dose)
Study: 35226640
Drug: Safety-net antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety-net antibiotic prescription (SNAP) offered to patients with AOM.
Study: 34987316
Drug: Directional Coronary
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directional Coronary Atherectomy (DCA) followed by drug-coated balloon (DCB) angioplasty
Study: 32592596
Drug: COC +
Normalized name: Combination oral contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC + VPR (2 mg/d vilaprisan)
Study: 32557558
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy alone
Study: 33840798
Drug: Wheat oral
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat oral immunotherapy (WOIT)
Study: 36430967
Drug: Melatonin 1
Normalized name: melatonin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1 mg/day for 1 year
Study: 32886189
Drug: 12-month exercise
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month exercise program (weekly supervised step aerobics, circuit exercises, and home training)
Study: 32938990
Drug: Inhaled prostaglandin-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled prostaglandin-E2 (PGE2) 100 μg
Study: 32938990
Drug: Inhaled bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bradykinin (BK) 200 μg
Study: 32513182
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg∙kg‐1)
Study: 36563900
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ferric carboxymaltose
Study: 33367545
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intensive chemotherapy without GO)
Study: 34498068
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IV acetaminophen
Study: 34193177
Drug: Sequential finger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential finger task in REs
Study: 34193177
Drug: Sequential reaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential reaching task in VEs
Study: 34257678
Drug: Ayurveda drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurveda drug regimen arm II
Study: 34257678
Drug: Ayurveda drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurveda drug regimen arm I
Study: 35688677
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (5 mg/kg) and 0.25% bupivacaine (1 mg/kg)
Study: 35688677
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (1 mg/kg)
Study: 35688677
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (NaCl)
Study: 33244709
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact (SSC) combined with maternal singing during music therapy (MT)
Study: 37315900
Drug: Daily probiotic
Normalized name: CVS Daily Probiotic Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily probiotic
Study: 35584639
Drug: Inference-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inference-based cognitive-behavioral therapy (I-CBT)
Study: 35584639
Drug: Appraisal-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appraisal-based cognitive behavioral therapy (A-CBT)
Study: 34113093
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (1 mg)
Study: 32323191
Drug: Rivaroxaban (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (once-daily dosing)
Study: 32323191
Drug: Rivaroxaban (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (both dosing periods)
Study: 35265985
Drug: Contezolid 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid 800 mg q12h
Study: 35265985
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg q12h
Study: 34880300
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (OT) 24 IU
Study: 33600918
Drug: Ashwagandha root
Normalized name: ashwagandha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha root extract (300 mg, twice daily for 8 weeks)
Study: 32125300
Drug: Individual milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with apical periodontitis of incisors, canines or premolars.
Study: 32125300
Drug: Individual milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with similar diagnosis and concomitant periodontitis of moderate severity.
Study: 32125300
Drug: Individual milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual milled transdental implants made of zirconium dioxide; patients with periapical destructive process of molars without periodontitis.
Study: 33608007
Drug: Targeted lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted lung denervation (TLD) therapy
Study: 35043428
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus hypomethylating agent (HMA)
Study: 35043428
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus low-dose cytarabine (LDAC)
Study: 33743831
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin treatment
Study: 33743831
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (local treatment)
Study: 34814867
Drug: cinpanemab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinpanemab, a monoclonal antibody against alpha‐synuclein
Study: 32054543
Drug: PS +
Normalized name: Spartan Nash 32 gauge 4 mm Pen Tips + 1C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS + FO (3.3 g/d PS and 450 mg EPA + 1500 mg DHA/d)
Study: 32054543
Drug: PS (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS (3.3 g/d)
Study: 32054543
Drug: FO (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: FO (450 mg EPA + 1500 mg DHA/d)
Study: 32776347
Drug: Home parenteral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home parenteral nutrition (PN) or customized intravenous fluid (IVF) support for IBD patients
Study: 34453208
Drug: Sensor Augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM)
Study: 32197714
Drug: Mind-body medicine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body medicine use among women with gynecological cancer
Study: 32197714
Drug: Mind-body medicine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body medicine use among women without gynecological cancer
Study: 34425226
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg testosterone enanthate per week in sesame oil)
Study: 35405085
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily)
Study: 35405085
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m2 once every 3 weeks)
Study: 33785481
Drug: Dose-dense temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-dense temozolomide plus zotiraciclib
Study: 33979763
Drug: TNX-102 SL
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-102 SL 5.6 mg
Study: 33979763
Drug: TNX-102 SL
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-102 SL 2.8 mg
Study: 32497023
Drug: l-Arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Arginine supplementation (0.05 mg/kg orally, twice daily)
Study: 32497023
Drug: l-Arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Arginine supplementation
Study: 35748393
Drug: Yohimbine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (10 mg, n=17)
Study: 35748393
Drug: Sulpiride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (200 mg, n=16)
Study: 39418346
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) alone
Study: 34240571
Drug: Temperature-controlled radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature-controlled radiofrequency (RF) treatment of the nasal valve
Study: 34049770
Drug: Intradermal acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acetylcholine (ACh) injection
Study: 35505467
Drug: Keverprazan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keverprazan 20 mg once daily
Study: 34311772
Drug: 15-min talocrural
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min talocrural joint manual therapy plus 30-min specific task-oriented training (group A)
Study: 33909360
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment at Guanyuan (CV 4), Shuidao (ST 28), Guilai (ST 29), Shenshu (BL 23), and Ciliao (BL 32), disperse-dense wave, 2 Hz/15 Hz frequency, once a day for 10 days per menstrual cycle for 3 menstrual cycles
Study: 33909360
Drug: Ibuprofen sustained-release
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen sustained-release capsules, 0.3 g each time, once a day for 10 days before menstruation
Study: 34142293
Drug: Personalized medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized medicine approaches (e.g., patient-derived tumor organoids)
Study: 32009195
Drug: mepolizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab (monoclonal antibody to IL-5) as an add-on therapy to glucocorticoid treatment
Study: 32354681
Drug: Physician-delivered step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Physician-delivered step count prescription
Study: 35418065
Drug: Daily contact
Normalized name: CONTACT LENS DAILY CLEANER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily contact testing (DCT) using a rapid Lateral Flow Device (LFD)
Study: 35320555
Drug: Alpha® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha® ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/30 g), applied two times daily for 4 consecutive courses of chemotherapy
Study: 35320555
Drug: Placebo ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment, applied two times daily for 4 consecutive courses of chemotherapy
Study: 35818363
Drug: Baricitinib in
Normalized name: Product containing baricitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib in combination with remdesivir therapy (BCT)
Study: 35818363
Drug: Remdesivir monotherapy
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir monotherapy (RMT)
Study: 32145827
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel plus ART
Study: 32145827
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide plus ART
Study: 32145827
Drug: Intravenous bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bleomycin and vincristine plus ART
Study: 33037803
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment with 1000 mg IV acetaminophen 20 min before surgery
Study: 33037803
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with 1000 mg IV acetaminophen after surgery
Study: 32171038
Drug: NDMC 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDMC 20 mg
Study: 32171038
Drug: NDMC 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDMC 60 mg
Study: 32171038
Drug: Clonazepam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1.5 mg
Study: 34383681
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment
Study: 32442673
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration (24 IU intranasally)
Study: 34369696
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment only (Control group).
Study: 34496300
Drug: Levonorgestrel 52
Normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52 mg intrauterine system (IUS) among women with heavy menstrual bleeding
Study: 34496300
Drug: Levonorgestrel 52
Normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52 mg intrauterine system (IUS) among users for contraception (comparison group)
Study: 36260832
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) + Reirradiation (re-RT) 35 Gy in 10 fractions with concurrent BEV IV 10 mg/kg every 2 weeks
Study: 33499543
Drug: Military Treatment
Normalized name: typhoid, parenteral, AKD (U.S. military)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Military Treatment Facility Engagement Committee (MTFEC)
Study: 35344464
Drug: sIPV (Sabin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIPV (Sabin inactivated poliovirus vaccine)
Study: 34965953
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment with IL-6 and HGF
Study: 34965953
Drug: Model based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model based on IL-6, HGF and bevacizumab treatment
Study: 36058418
Drug: Instructed positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructed positive interaction + intranasal oxytocin
Study: 36058418
Drug: Control +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control + intranasal oxytocin
Study: 34531736
Drug: Oroxylum indicum
Normalized name: Canarium indicum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oroxylum indicum extract (500 mg, twice daily)
Study: 34918028
Drug: Efavirenz (EFV1)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV1) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Study: 34918028
Drug: Efavirenz (EFV2)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV2) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Study: 34887285
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of zoledronic acid
Study: 37341961
Drug: Etanercept (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.8 mg/kg)
Study: 34661664
Drug: High-dose deutetrabenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose deutetrabenazine (up to 48 mg/d)
Study: 34661664
Drug: Low-dose deutetrabenazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose deutetrabenazine (up to 36 mg/d)
Study: 34661664
Drug: High-dose deutetrabenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose deutetrabenazine
Study: 34661664
Drug: Low-dose deutetrabenazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose deutetrabenazine
Study: 34391242
Drug: Fascial therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy, strength training, and kinesiotaping
Study: 36450422
Drug: Continue RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue RAS inhibiting therapy
Study: 36450422
Drug: Discontinue RAS
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discontinue RAS inhibiting therapy
Study: 36450422
Drug: Continue RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue RAS inhibiting therapy (mechanistic substudy)
Study: 36450422
Drug: Discontinue RAS
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discontinue RAS inhibiting therapy (mechanistic substudy)
Study: 33386890
Drug: Grape powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape powder (46 g, equivalent to 252 g fresh grapes)
Study: 39675209
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine
Study: 35962939
Drug: Tanezumab 10
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 10 mg (every 8 weeks)
Study: 35962939
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg (every 8 weeks)
Study: 35962939
Drug: Tramadol (100–300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100–300 mg/day)
Study: 34491803
Drug: SPR720 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR720 (100 to 2000 mg single doses or 500 to 1500 mg daily doses for 7 or 14 days)
Study: 32744369
Drug: 0.01% bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% bimatoprost ophthalmic solution
Study: 33933738
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum calcium levels (per 0.5 mg/dL)
Study: 32737900
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide at a dose of 20 ppm added to the sweep gas during CPB
Study: 33611164
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine (mVNR) at a fixed dose of 50 mg × 3
Study: 33611164
Drug: Standard schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schedule of vinorelbine (60-80 mg/m2 weekly)
Study: 33611164
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine (mVNR)
Study: 34271465
Drug: Indian mustard
Normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indian mustard (Brassica juncea L.)
Study: 36223056
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly injections of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Study: 36223056
Drug: 1 initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 initial injection of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Study: 32522420
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HLA)-based vaginal gel, used daily for the first 2 weeks, then 3 times/week until weeks 12-14, increased to 5 times/week for non-responders.
Study: 32522420
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HLA)-based vaginal gel
Study: 34213494
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg intravenous injection)
Study: 34213494
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg intravenous injection)
Study: 34213494
Drug: Nitroglycerin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.5 μg/kg intravenous injection)
Study: 32338932
Drug: Integrative cognitive‐affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive‐affective therapy for BED (ICAT‐BED)
Study: 32338932
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help cognitive-behavioral therapy (CBTgsh)
Study: 33092527
Drug: Intravesical dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical dexmedetomidine instillation (0.5 μg/kg and normal saline 20 mL)
Study: 34429002
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with allergen extracts of D. pteronyssinus and D. farinae (50/50%) in SQ-HDM SLIT tablets
Study: 35367007
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for 17 cycles
Study: 34187535
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment + Gegen Qinlian decoction placebo + Erbai drink placebo
Study: 38634928
Drug: Pembrolizumab (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (second-line therapy)
Study: 32886108
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g mycoprotein (31.5 g protein; MYCO; n = 10)
Study: 32886108
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g BCAA-enriched mycoprotein (18.7 g protein; ENR; n = 9)
Study: 32808025
Drug: Bi-anodal tDCS
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-anodal tDCS over the PFC regions (2 mA, 20 minutes, twice daily for 5 weeks)
Study: 35039258
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (erythromycin sequential therapy plus azithromycin)